Home / Market News / $RVMD

$RVMD news and market catalysts

The 45 most recent market catalysts affecting $RVMD, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

45 catalysts 5 high impact 33 bullish 4 bearish Pharmaceuticals
Nov 16, 2026 Corporate Catalyst Bullish Impact 75
European Commission Approves Revolution Medicines' RASONQUE (daraxonrasib) for Metastatic Pancreatic Cancer
Revolution Medicines announced that the European Commission has approved RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma. This is a significant regulatory achievem…
Nov 13, 2026 Corporate Catalyst Bearish Impact 55
Morgan Stanley Lowers Price Target for Revolution Medicines
Morgan Stanley, a prominent investment bank, has reduced its price target for Revolution Medicines (RVMD) from $272 to $247. This action signals a less optimistic outlook from the …
Nov 12, 2026 Corporate Catalyst Bearish Impact 75
FDA Suspends Fast-Track Drug Review Initiative
The FDA has suspended its 'Commissioner's National Priority Voucher Program,' an initiative designed to fast-track drug reviews for national health priorities. This decision stems …
Nov 6, 2026 Corporate Catalyst Bullish Impact 65
HC Wainwright & Co. Maintains Buy Rating and Raises Price Target for Revolution Medicines
On November 6, 2026, HC Wainwright & Co. reaffirmed its 'Buy' rating for Revolution Medicines (RVMD) and raised its price target by 25% to $350. This action signals strong analyst …
Nov 5, 2026 Corporate Catalyst Bullish Impact 65
RBC Raises Price Target on Revolution Medicines
RBC has raised its price target for Revolution Medicines (RVMD) from $260 to $321, signaling increased confidence in the company's future performance. This positive adjustment stem…
Nov 4, 2026 Corporate Catalyst Neutral Impact 75
Revolution Medicines Reports Third Quarter 2026 Financial Results
Revolution Medicines reported a net loss of $407.5 million for Q3 2026, significantly wider than the $305.2 million loss in Q3 2025. This increased loss, despite the positive miles…
Oct 23, 2026 Corporate Catalyst Bullish Impact 75
Revolution Medicines Presents Overall Survival Data for RASONQUE™ at ESMO 2026
Revolution Medicines announced positive overall survival data for its drug RASONQUE from a Phase 3 trial, presented at ESMO 2026. This is significant because it reinforces the effi…
Oct 20, 2026 Corporate Catalyst Bullish Impact 85
Revolution Medicine shares are trading higher. The company announced that it has begun treating patients in its Phase 3 clinical trial of zoldonrasib in combination with pembrolizumab plus chemotherapy to treat metastatic non-squamous non-small cell lung cancer.
The initiation of a Phase 3 clinical trial is a major milestone for any pharmaceutical company, significantly reducing the regulatory and scientific risk associated with a drug. Fo…
Oct 20, 2026 Corporate Catalyst Neutral Impact 75
Revolution Medicines Begins Treating Patients In Phase 3 RASolve 308 Trial
This headline signifies a crucial step for Revolution Medicines (RVMD) as it moves its lead RAS-targeted therapy into late-stage clinical trials. Success in Phase 3 could lead to m…
Oct 19, 2026 Corporate Catalyst Bullish Impact 55
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $241
Truist Securities analyst Gregory Renza maintained a 'Buy' rating on Revolution Medicines (RVMD) and raised the price target from $240 to $241. This action signals continued analys…
Oct 16, 2026 Corporate Catalyst Bullish Impact 75
Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow
William Blair initiated coverage on Revolution Medicines (RVMD) with an Outperform rating and a $226 price target, a significant vote of confidence for the biotechnology company. T…
Oct 16, 2026 Corporate Catalyst Neutral Impact 60
William Blair Initiates Coverage On Revolution Medicines with Outperform Rating
William Blair's initiation of coverage on Revolution Medicines with an Outperform rating is a positive development for the company. Analyst coverage, especially with a favorable ra…
Oct 15, 2026 Corporate Catalyst Neutral Impact 55
Needham Reiterates Buy on Revolution Medicines, Maintains $275 Price Target
Needham analyst Ami Fadia has reaffirmed a 'Buy' rating and a $275 price target for Revolution Medicines. This action signals that the analyst's positive outlook on the company rem…
Oct 14, 2026 Corporate Catalyst Bullish Impact 55
Revolution Medicines shares are trading higher after RBC Capital raised its price target on the stock from $259 to $260.
This headline indicates a positive, albeit minor, corporate catalyst for Revolution Medicines. RBC Capital's price target increase from $259 to $260 is a very small adjustment, sug…
Oct 14, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $260
RBC Capital's analyst Leonid Timashev has maintained an 'Outperform' rating for Revolution Medicines (RVMD) and raised the price target from $259 to $260. This action signals conti…
Oct 8, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $259
RBC Capital's analyst Leonid Timashev maintained an 'Outperform' rating on Revolution Medicines (RVMD) and raised the price target from $251 to $259. This action signals continued …
Oct 7, 2026 Corporate Catalyst Bullish Impact 55
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $240
Truist Securities analyst Gregory Renza has maintained a 'Buy' rating on Revolution Medicines (RVMD) and raised the price target from $239 to $240. This action signals ongoing anal…
Oct 5, 2026 Corporate Catalyst Neutral Impact 65
Revolution Medicines Begins Treating Patients In RASolute 309, Global, Randomized Phase 3 Clinical Trial Evaluating Combination Of RASONQUE And Zoldonrasib As First-Line Treatment In Adult Patients With Metastatic RAS G12D PDAC
Revolution Medicines has begun treating patients in its RASolute 309 Phase 3 clinical trial, evaluating a combination of RASONQUE and zoldonrasib for metastatic RAS G12D pancreatic…
Sep 28, 2026 Corporate Catalyst Neutral Impact 65
Brookline Capital Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $318
Brookline Capital's analyst Leah Rush initiated coverage on Revolution Medicines (RVMD) with a 'Buy' rating and a significant price target of $318. This event is a positive catalys…
Sep 24, 2026 Corporate Catalyst Neutral Impact 75
Goldman Sachs Reinstates Buy on Revolution Medicines, Announces $267 Price Target
Goldman Sachs analyst Andrea Newkirk reinstated a 'Buy' rating on Revolution Medicines (RVMD) and announced a $267 price target. This is a significant positive development for RVMD…
Sep 21, 2026 Corporate Catalyst Bullish Impact 65
B of A Securities Maintains Buy on Revolution Medicines, Raises Price Target to $265
B of A Securities, through analyst Alec Stranahan, has maintained its 'Buy' rating on Revolution Medicines (RVMD) and significantly raised its price target from $225 to $265. This …
Sep 14, 2026 Corporate Catalyst Bullish Impact 95
Revolution Medicines Says FDA Granted Breakthrough Therapy Designation To RASONQUE In Combination With Gemcitabine And Nab-Paclitaxel For Treatment-Naive Metastatic Pancreatic Adenocarcinoma
The FDA's Breakthrough Therapy Designation is a significant regulatory milestone, indicating preliminary clinical evidence of substantial improvement over available therapies for a…
Sep 10, 2026 Corporate Catalyst Neutral Impact 65
Morgan Stanley Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Target of $255
Morgan Stanley's initiation of coverage on Revolution Medicines (RVMD) with an 'Overweight' rating and a substantial $255 price target is a significant event for the company. This …
Sep 9, 2026 Corporate Catalyst Bullish Impact 55
Stifel Maintains Buy on Revolution Medicines, Raises Price Target to $230
Stifel's analyst Laura Prendergast maintained a 'Buy' rating for Revolution Medicines (RVMD) and raised the price target from $215 to $230. This action signals a positive outlook f…
Sep 2, 2026 Corporate Catalyst Bearish Impact 55
Why Are 42% of US Cancer Patients Draining Their Life Savings in Two Years? Bernie Sanders Has a $400,000 Answer
Senator Bernie Sanders has publicly criticized the high cost of new cancer drugs, specifically citing Revolution Medicines' (RVMD) newly approved pancreatic cancer drug, Rasonque, …
Aug 31, 2026 Corporate Catalyst Bullish Impact 55
Needham Maintains Buy on Revolution Medicines, Raises Price Target to $275
This 8-K filing discloses that Needham, through analyst Ami Fadia, has maintained a 'Buy' rating on Revolution Medicines (RVMD) and raised its price target from $240 to $275. This …
Aug 28, 2026 Corporate Catalyst Bullish Impact 55
UBS Maintains Buy on Revolution Medicines, Raises Price Target to $265
UBS analyst Michael Yee maintained a 'Buy' rating on Revolution Medicines (RVMD) and raised the price target from $220 to $265. This action indicates a strengthened positive outloo…
Aug 28, 2026 Corporate Catalyst Bullish Impact 55
Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $275
Guggenheim analyst Michael Schmitz has raised the price target for Revolution Medicines (RVMD) from $240 to $275 while maintaining a 'Buy' rating. This action indicates a strengthe…
Aug 27, 2026 Corporate Catalyst Bullish Impact 95
Revolution Medicines Stock Trades Higher Following Landmark FDA Approval for Pancreatic Cancer Drug
Revolution Medicines (RVMD) has received FDA approval for Rasonque, its pancreatic cancer drug, marking a significant milestone as the first approved targeted therapy from a new cl…
Aug 27, 2026 Corporate Catalyst Bullish Impact 55
Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $260
Oppenheimer analyst Jay Olson has maintained an 'Outperform' rating on Revolution Medicines (RVMD) and raised the price target from $230 to $260. This action signals a strengthened…
Aug 27, 2026 Corporate Catalyst Bullish Impact 65
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $251
RBC Capital analyst Leonid Timashev has maintained an Outperform rating on Revolution Medicines (RVMD) and significantly raised the price target from $203 to $251. This action indi…
Aug 27, 2026 Corporate Catalyst Bullish Impact 55
Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $225
Wedbush analyst Robert Driscoll has updated his outlook on Revolution Medicines, increasing the price target for RVMD from $201 to $225 and reaffirming an Outperform rating. This a…
Aug 27, 2026 Corporate Catalyst Bullish Impact 55
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $239
Truist Securities analyst Gregory Renza maintained a 'Buy' rating on Revolution Medicines and raised the price target from $231 to $239. This action signals continued bullish senti…
Aug 27, 2026 Corporate Catalyst Bullish Impact 65
Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $320
Evercore ISI Group's analyst Cory Kasimov maintained an 'Outperform' rating on Revolution Medicines (RVMD) and raised the price target from $230 to $320. This significant increase …
Aug 26, 2026 Corporate Catalyst Bullish Impact 95
Revolution Medicines Wins FDA Nod for First-Of-Its-Kind Pancreatic Cancer Drug
Revolution Medicines (RVMD) announced FDA approval for Rasonque (daraxonrasib), a novel pancreatic cancer drug. This is a major milestone as Rasonque is the first approved targeted…
Aug 21, 2026 Corporate Catalyst Bullish Impact 55
Bernstein Maintains Market Perform on Revolution Medicines, Raises Price Target to $179
Bernstein analyst Jeffrey Walch increased the price target for Revolution Medicines (RVMD) from $151 to $179, signaling an improved valuation outlook for the company. Despite the h…
Aug 11, 2026 Corporate Catalyst Bullish Impact 55
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $231
Truist Securities analyst Gregory Renza maintained a 'Buy' rating on Revolution Medicines (RVMD) and raised the price target from $210 to $231. This action signals a continued posi…
Aug 6, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $203
RBC Capital analyst Leonid Timashev maintained an 'Outperform' rating on Revolution Medicines (RVMD) and raised the price target from $182 to $203. This action signals a strengthen…
Aug 6, 2026 Corporate Catalyst Bullish Impact 55
Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $201
Wedbush analyst Robert Driscoll has maintained an 'Outperform' rating for Revolution Medicines (RVMD) and raised the price target from $192.1 to $201. This action signals continued…
Aug 6, 2026 Corporate Catalyst Bullish Impact 55
Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $230
Evercore ISI Group's analyst Cory Kasimov maintained an 'Outperform' rating for Revolution Medicines (RVMD) and raised the price target from $220 to $230. This action signals a pos…
Aug 6, 2026 Corporate Catalyst Bullish Impact 55
Needham Maintains Buy on Revolution Medicines, Raises Price Target to $240
Needham analyst Ami Fadia has maintained a 'Buy' rating on Revolution Medicines (RVMD) and raised the price target from $236 to $240. This action signals continued bullish sentimen…
Aug 5, 2026 Corporate Catalyst Bearish Impact 95
Revolution Medicines Q2 EPS $(3.06) Misses $(1.98) Estimate
Revolution Medicines (RVMD) announced Q2 earnings per share of $(3.06), significantly missing the analyst consensus estimate of $(1.98). This 54.55% miss, coupled with a 133.59% in…
Jul 23, 2026 Corporate Catalyst Bullish Impact 75
Revolution Medicines shares are trading higher after Wedbush raised its price target on the stock from $181 to $192.1.
The Wedbush price target increase from $181 to $192.1 for Revolution Medicines (RVMD) is a strong positive catalyst, signaling increased analyst confidence in the company's valuati…
Jul 23, 2026 Corporate Catalyst Bullish Impact 55
Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $192.1
Wedbush analyst Robert Driscoll has raised the price target for Revolution Medicines (RVMD) from $181 to $192.1 while maintaining an Outperform rating. This action signals a positi…
Jul 20, 2026 Corporate Catalyst Bullish Impact 55
Needham Maintains Buy on Revolution Medicines, Raises Price Target to $236
Needham analyst Ami Fadia has maintained a 'Buy' rating on Revolution Medicines (RVMD) and raised the price target from $235 to $236. This action signals continued analyst confiden…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.